NASDAQ:AKTX Akari Therapeutics Q4 2025 Earnings Results & Report $8.77 +0.64 (+7.87%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$9.06 +0.29 (+3.25%) As of 10/9/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Akari Therapeutics missed analyst earnings expectations in its Q4 2025 results, released March 30, 2026. The company reported EPS of -$2.68 versus the -$0.03 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 30, 2026TimeAfter Market ClosesConference Call7:00 AM ET Akari Therapeutics EPS ResultsActual EPS-$2.68Consensus EPS -$0.03Beat/MissMissed by -$2.65One Year Ago EPSN/AAkari Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsAkari Therapeutics' Q3 2026 earnings is estimated for Friday, December 4, 2026, based on past reporting schedulesConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Akari Therapeutics Q4 2025 Earnings FAQ Did Akari Therapeutics beat earnings estimates for Q4 2025? Akari Therapeutics (NASDAQ:AKTX) reported earnings of -$2.68 per share for Q4 2025, missing the consensus estimate of -$0.03. The report was announced on Monday, March 30, 2026. When is Akari Therapeutics' next earnings date? Akari Therapeutics' next earnings date is estimated for Friday, December 4, 2026. MarketBeat tracks confirmed and estimated earnings dates for Akari Therapeutics on the company's earnings history page. Akari Therapeutics Earnings HeadlinesAkari Therapeutics (NASDAQ:AKTX) Stock Price Breaks Above 50 Day Moving Average - Here's What HappenedOctober 6, 2026 | americanbankingnews.comAkari Expands IP Portfolio With PCT Filing For PH1 ADC PayloadOctober 1, 2026 | rttnews.comFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.October 10 at 1:00 AM | Monetary Gold (Ad)Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in CancersOctober 1, 2026 | globenewswire.comAkari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare ForumsSeptember 8, 2026 | globenewswire.comAkari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand ConferenceAugust 27, 2026 | globenewswire.comSee More Akari Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Akari Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akari Therapeutics and other key companies, straight to your email. Email Address About Akari TherapeuticsAkari Therapeutics (NASDAQ:AKTX), Plc (NASDAQ: AKTX) is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on regulating the complement system and inflammatory pathways that contribute to tissue damage. Akari’s lead investigational product is nomacopan, a recombinant small protein designed to inhibit complement component 5 (C5) and leukotriene B4 (LTB4). The company is also developing a long-acting formulation known as PAS-nomacopan. These programs have been evaluated or are being developed for conditions including pediatric hematopoietic stem cell transplant-associated thrombotic microangiopathy and bullous pemphigoid. Akari Therapeutics conducts its development activities through operations and clinical programs involving the United States and the United Kingdom. The company’s therapies remain investigational and are subject to clinical testing and regulatory review; no assurance can be given that they will receive approval or become commercially available.View Akari Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
